h***e
发帖数: 7320 | 1 中国本土的制药公司 （北京科新），专门做疫苗的，公司成立于2001年，旗下共有四
个产品
甲肝灭活疫苗Healive；甲乙肝联合疫苗Bilive； 流感裂解疫苗安尔来福Anflu； H1N1
流感疫苗盼尔来福Panflu
目前被炒得很热的是最后一个对于H1N1的疫苗panflu. 粗粗做了下research, 感觉公司
的经营状况良好，资金充足，产品供不应求，免疫性和安全性都良好；同时，它家
research和development共同发展，最近两年也有不错的研究成果发表。
先收集了一些关于panflu的新闻如下
BEIJING, August 31 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (NYSE Amex:
SVA - News), a leading provider of biopharmaceutical products in China,
announced today that Sinovac's H1N1 vaccine has passed the experts
evaluation organized by State Food and Drug Administration (SFDA). The
vaccine is expected to obtain the production license within this week.
BEIJING, Sept. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a
leading provider of biopharmaceutical products in China, announced today
that the State Food and Drug Administration (SFDA) has approved the
registration application for PANFLU.1, Sinovac's H1N1 vaccine, and has
issued Sinovac a production license for this vaccine.
SEOUL, Sept. 17 (Yonhap) -- South Korea's Boryung Pharmaceutical Co. said
Thursday that it has applied for permission to begin domestic sales of a
Chinese made vaccine for the Influenza A (H1N1) virus within the year. The
company signed a contract with China's Sinovac Biotech Ltd. earlier this
month to import as many as 10 million doses of the vaccine, enough to
inoculate some 5 million people against the contagious disease.
From Yahoo MSG Sep 30th, NEW YORK (AP) -- Sinovac Biotech Ltd. said
Wednesday the Chinese government purchased 3 million more doses of Sinovac's
Panflu.1 swine flu vaccine, bringing the total order to 6.3 million doses.
BEIJING, Oct. 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA),
a leading developer and provider of vaccines in China, announced today that
its wholly-owned subsidiary, Sinovac Biotech (Hong Kong) Ltd, has received
the Certificate of Approval to distribute Panflu(TM) (H5N1), its H5N1 (bird
flu) pandemic influenza vaccine, in Hong Kong. The certificate is valid
through September 13, 2014 and thereafter will be renewable for periods of
five years at a time, subject to payment of the registration fee. |
|
